Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTX Context Therapeutics Inc.

Trading 04-27 10:10:11 EDT

2.25

-0.01

-0.44%

High2.31	Low2.19	Vol232.21K
Open2.26	D1 Closing2.26	Amplitude5.31%
Mkt Cap206.73M	Tradable Cap89.71M	Total Shares91.88M
T/O522.61K	T/O Rate0.58%	Tradable Shares39.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNTX","market":"US","secType":"STK","nameCN":"Context Therapeutics Inc.","latestPrice":2.25,"timestamp":1777299007732,"preClose":2.26,"halted":0,"volume":232208,"delay":0,"changeRate":-0.004424778761061853,"floatShares":39871400,"shares":91879177,"eps":-0.38,"marketStatus":"Trading","change":-0.01,"latestTime":"04-27 10:10:11 EDT","open":2.26,"high":2.31,"low":2.19,"amount":522614.8251184,"amplitude":0.053097,"askPrice":2.25,"askSize":337,"bidPrice":2.24,"bidSize":838,"shortable":3,"etf":0,"ttmEps":-0.38,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777320000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1634702400000,"exchange":"NASDAQ","adjPreClose":2.26,"preHourTrading":{"tag":"盘前","latestPrice":2.27,"preClose":2.26,"latestTime":"09:28 EDT","volume":1616,"amount":3667.4098688,"timestamp":1777296486076,"change":0.01,"changeRate":0.004425,"amplitude":0.004027},"postHourTrading":{"tag":"盘后","latestPrice":2.26,"preClose":2.26,"latestTime":"17:29 EDT","volume":12076,"amount":26943.3559,"timestamp":1777066176026,"change":0,"changeRate":0,"amplitude":0.053097},"volumeRatio":1.691692},"requestUrl":"/m/hq/s/CNTX","defaultTab":"news","newsList":[{"id":"2628784523","title":"Context Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2628784523","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628784523?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:30","pubTimestamp":1776457819,"startTime":"0","endTime":"0","summary":"Context Therapeutics scheduled 2026 annual stockholder meeting for June 24, 2026 in virtual format.Vote set on election of seven director nominees to serve until 2027 annual meeting.Ballot includes ratification of CohnReznick as independent registered public accounting firm for fiscal 2026.Shareholders to consider charter amendment to raise authorized common shares to 300,000,000 from 200,000,000.Proposal also seeks approval to adjourn meeting if needed to secure additional votes on authorized-share increase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDLxG0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625094657","title":"Neogen names Jennifer Evans Stacey chief legal, compliance officer, board secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2625094657","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625094657?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:00","pubTimestamp":1775649641,"startTime":"0","endTime":"0","summary":"Neogen named Jennifer Evans Stacey as chief legal and compliance officer, appointing her as board secretary.Stacey most recently served as chief legal and compliance officer, secretary at Galera Therapeutics.Her prior senior roles include chief legal officer posts across life sciences organizations, including The Wistar Institute, Antares Pharma, Auxilium Pharmaceuticals.Stacey also serves on board of Context Therapeutics.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLLbZsG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211817866.USD","HALO","GRTX","BK4007","NEOG","CNTX","BK4139","LU0053671581.USD","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625779601","title":"JonesTrading Remains a Buy on Context Therapeutics (CNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625779601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625779601?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:39","pubTimestamp":1775507965,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Context Therapeutics, with a price target of $7.00. Roy covers ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624501915","title":"Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), Context Therapeutics (CNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624501915","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624501915?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:00","pubTimestamp":1775134833,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Femasys (FEMY) and Context Therapeutics (CNTX) with ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-femasys-femy-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-femasys-femy-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTX","FEMY","LABU","BK4588","LU0029874061.USD","BK4584","BLSX","BK4137","BK4585","BK4539","BLSG","LU0128526141.USD","BK4112","BK4007","XBI","BK4082","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624372509","title":"Context Therapeutics Gains FDA Fast Track for CTIM-76","url":"https://stock-news.laohu8.com/highlight/detail?id=2624372509","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624372509?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:11","pubTimestamp":1775131872,"startTime":"0","endTime":"0","summary":"An update from Context Therapeutics ( ($CNTX) ) is now available. On April 2, 2026, Context Therapeutics announced that the U.S. Food and Drug Admi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-gains-fda-fast-track-for-ctim-76?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-gains-fda-fast-track-for-ctim-76?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CNTX","LENZ","BK4007","LABU","BK4539","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506937","title":"Context Therapeutics granted Fast Track Designation to CTIM-76 by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506937","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506937?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:54","pubTimestamp":1775130869,"startTime":"0","endTime":"0","summary":"Context Therapeutics (CNTX) announced that the FDA has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-granted-fast-track-designation-to-ctim-76-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-granted-fast-track-designation-to-ctim-76-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","CNTX","LABU","BK4588","BK4585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624055455","title":"Context Therapeutics’ CTIM-76 wins FDA fast-track status for platinum-resistant ovarian cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2624055455","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624055455?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:30","pubTimestamp":1775129452,"startTime":"0","endTime":"0","summary":"FDA granted Fast Track designation to Context Therapeutics’ CTIM-76 for treatment of platinum-resistant ovarian cancer in patients who have received all standard-of-care therapies.CTIM-76 is in Phase 1a testing; interim data expected in June 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLVgNTs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","BK4112","BK4007","CNTX","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014021.USD","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014039.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624950553","title":"Context Therapeutics - Ctim-76 Phase 1a Trial Ongoing, Interim Data Expected June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624950553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624950553?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:30","pubTimestamp":1775129400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA4S1D0H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624055585","title":"Context Therapeutics Announces Ctim-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2624055585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624055585?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:30","pubTimestamp":1775129400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA4S1D0H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622024521","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024521?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:00","pubTimestamp":1774432800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA","DEFT","NKE","CNTX","CGNT","DMAC","HYPD","CNTB","BAK","FEMY","MKC","AIRJ","KOD","CMC","BTGO","FUL","BHST","BCAX","EQ","IMNN","AGX","FDS","IMDX","CTAS","BNZI","ABOS","AIRO","RNXT","BIRD","GOVX","JILL","JEF","CGTX","DERM","JBS","BITF","AURA","IKT","CDLR","CHWY","DOO","EDAP","EPAC","CELC","AUTL","KALV","HUMA","BYND","CCL"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621402066","title":"Guggenheim Reaffirms Their Buy Rating on Context Therapeutics (CNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621402066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621402066?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:55","pubTimestamp":1774349758,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Paul Jeng from Guggenheim reiterated a Buy rating on Context Therapeutics, with a price target of $5.00. The compan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621082934","title":"Context Therapeutics FY Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2621082934","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621082934?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:52","pubTimestamp":1774299120,"startTime":"0","endTime":"0","summary":"Context Therapeutics  reported a FY net loss of $0.38 per diluted share late Monday, narrowing from a loss of $0.46 a year earlier.Analysts polled by FactSet expected a loss of $0.35.The company ended the year with $94.4 million in cash and equivalents. It expects this will be sufficient to fund operations into mid-2027.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","CNTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621223082","title":"Context Therapeutics Highlights Evolving T Cell Engager Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2621223082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621223082?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:49","pubTimestamp":1774298978,"startTime":"0","endTime":"0","summary":"Context Therapeutics ( ($CNTX) ) just unveiled an update. On March 23, 2026, Context Therapeutics Inc. updated its corporate presentation for inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-highlights-evolving-t-cell-engager-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-highlights-evolving-t-cell-engager-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","CNTX","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621844220","title":"BRIEF-Context Therapeutics Reports Full Year 2025 Operating And Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621844220","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621844220?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:34","pubTimestamp":1774298054,"startTime":"0","endTime":"0","summary":"BRIEF-Context Therapeutics Reports Full Year 2025 Operating And Financial ResultsMarch 23 (Reuters) - Context Therapeutics Inc CNTX.O:CONTEXT THERAPEUTICS REPORTS FULL YEAR 2025 OPERATING AND FINANCIA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA5ZV2FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621335084","title":"Context Therapeutics targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621335084","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621335084?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:17","pubTimestamp":1774297039,"startTime":"0","endTime":"0","summary":"Context outlined a solid-tumor T-cell engager bispecific antibody portfolio, positioning multiple programs to generate clinical readouts in 2026 that could support partnering and future development decisions.CTIM-76 interim Phase 1a data is expected in June 2026, creating a potential near-term catalyst for differentiation in CLDN6-targeted solid-tumor approaches.CT-95 interim Phase 1a data is expected in September 2026, which may help clarify competitive positioning in mesothelin-targeted therapies across several tumor types.CT-202 is expected to enter Phase 1 in Q3 2026, expanding the pipeline into Nectin-4 and potentially broadening commercial optionality beyond the current clinical-stage assets.Cash and cash equivalents totaled USD 66.0 million as of December 31, 2025, with funding expected to extend into mid-2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLt9lx3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","CNTX","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014021.USD","SG9999014005.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","BK4585","BK4007","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","NDAQ","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084381","title":"Context Therapeutics: Cash and Cash Equivalents of $66 Mln as of December 31, 2025 Expected to Fund Operations Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084381","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084381?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:16","pubTimestamp":1774297000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA5ZV2FX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621817150","title":"Context Therapeutics FY 2025 net loss widens 35% to USD 36 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621817150","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621817150?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:10","pubTimestamp":1774296636,"startTime":"0","endTime":"0","summary":"Context Therapeutics published an annual report on Form 10-K, reporting a net loss of USD 36.1 million and a loss from operations of USD 39.7 million.Research and development expense rose 40% to USD 31.9 million, driven mainly by higher clinical costs for CTIM-76 and higher contract manufacturing and preclinical spending for CT-202, plus higher personnel-related costs.General and administrative expense increased 9% to USD 7.8 million, primarily due to higher salaries and personnel-related costs.Cash and cash equivalents were USD 66.0 million, which management said is expected to fund operations into mid-2027, including Phase 1a dose escalation for CTIM-76 and CT-95 and initiation of patient enrollment for CT-202.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9tBBTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621583774","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2621583774","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621583774?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:00","pubTimestamp":1774260000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTAS","CCL","KALV","FEMY","DPRO","EPAC","BAK","BYND","IMNN","ABVX","DERM","GOVX","ABOS","ACHV","BCAX","FBRX","FENC","CNTA","DEFT","GUTS","CHWY","KBH","AGX","CMC","EQ","FUL","HSAI","BZAI","IKT","CNTB","CGNT","AIR","CNTX","JEF","AVTX","JBS","CNXC","ABSI","EDAP","HYPD","BRZE","CNM","DOO","CELC","HUMA","IMDX","MXCT","BTGO","AUTL","EVTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782840","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782840","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620782840?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:00","pubTimestamp":1774000800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTAS","KOD","KRMN","KALV","FEMY","EPAC","BAK","BYND","IMNN","ABVX","DERM","GOVX","ACHV","BCAX","FBRX","FENC","CNTA","GUTS","FUFU","ALMS","CHWY","KBH","AGX","CMC","EQ","FUL","HSAI","BZAI","IKT","CNTB","CGNT","AIR","CNTX","JEF","AVTX","JBS","CNXC","ABSI","EDAP","HYPD","CNM","BRZE","DOO","CELC","HUMA","MXCT","BTGO","EVTL","CUK"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620425172","title":"Context Therapeutics to present CT-202 preclinical data at AACR Annual Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620425172","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620425172?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919854,"startTime":"0","endTime":"0","summary":"Context will present a poster on CT-202 at the AACR Annual Meeting 2026 in San Diego on April 21, 2026, from 9:00 a.m. to 12:00 p.m. PT.The presentation is listed under the Clinical Research category in session PO.CL05.12.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbSwLKM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","BK4585","BK4007","IE00BGHQF748.EUR","BK4588","NDAQ","CNTX","LU0314104364.USD","SG9999014021.USD","LU2210150020.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.contexttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.07},{"period":"1month","weight":-0.1536},{"period":"3month","weight":0.2486},{"period":"6month","weight":0.7937},{"period":"1year","weight":1.26},{"period":"ytd","weight":0.5374}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.188281},{"month":2,"riseRate":0.2,"avgChangeRate":-0.080088},{"month":3,"riseRate":0.6,"avgChangeRate":-0.010229},{"month":4,"riseRate":0.4,"avgChangeRate":-0.008943},{"month":5,"riseRate":0.75,"avgChangeRate":0.295099},{"month":6,"riseRate":0.75,"avgChangeRate":0.233367},{"month":7,"riseRate":0.5,"avgChangeRate":-0.057392},{"month":8,"riseRate":0.75,"avgChangeRate":0.057821},{"month":9,"riseRate":0.5,"avgChangeRate":0.000078},{"month":10,"riseRate":0.75,"avgChangeRate":0.018618},{"month":11,"riseRate":0.6,"avgChangeRate":-0.036732},{"month":12,"riseRate":0.4,"avgChangeRate":-0.161685}],"exchange":"NASDAQ","name":"Context Therapeutics Inc.","nameEN":"Context Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Context Therapeutics Inc.,CNTX,Context Therapeutics Inc.股票,Context Therapeutics Inc.股票老虎,Context Therapeutics Inc.股票老虎国际,Context Therapeutics Inc.行情,Context Therapeutics Inc.股票行情,Context Therapeutics Inc.股价,Context Therapeutics Inc.股市,Context Therapeutics Inc.股票价格,Context Therapeutics Inc.股票交易,Context Therapeutics Inc.股票购买,Context Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction